Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary
18/12/2024 17:28
* Neurosense Therapeutics Ltd NRSN.OQ reported a quarterly
adjusted loss of 11 cents per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of 10 cents. The mean expectation of
two analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -21 cents
to -11 cents per share.
* Reported revenue was zero; analysts expected zero.
* Neurosense Therapeutics Ltd's reported EPS for the quarter
was a
loss of 11 cents.
* The company reported a quarterly loss of $2.15 million.
* Neurosense Therapeutics Ltd shares had fallen by 14.2%
this
quarter and gained 38.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 23.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $7.50
This summary was machine generated from LSEG data December 18 at
05:27 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.16 -0.11 Beat
Jun. 30 2024 -0.20 -0.02 Beat
Mar. 31 2024 -0.20 -0.35 Missed
Dec. 31 2023 -0.20 -0.16 Beat